Degenerative disc disease refers to symptoms of back or neck pain caused by wear-and-tear on a spinal disc. In some cases, degenerative disc disease also cause weakness, numbness, and hot shooting pains in the arms or legs (radicular pain). Degenerative disc disease typically consists of a low-level chronic pain with intermittent episodes of more severe pain. Degenerative disc diseases are very frequent and debilitating disorders, and R&D activities surrounding this disease are highly cost intensive. Hence, many fund raising companies and manufacturers are engaged in raising funds for their research regarding the treatment of degenerative disc diseases. Depending upon the level of pain, degenerative disc disease can be treated with two common processes which are non-surgical and spinal fusion. Non-surgical treatments include medications, physical therapy, and chiropractic care. Whereas, spinal fusion is a procedure used to surgically treat degenerative disc disease.
Market Dynamics
Key players in the market are focused on growth strategies such as product launch and approval which is expected to drive the growth of market over forecast period. For instance, in April 2021, Cerapedics Inc. an ortho-biologics company, announced that the U.S. Food and Drug Administration (FDA) granted breakthrough device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). Moreover, in February 2019, FibroGenesis, a company focused on regrowth of the spinal disc nucleus using its universal donor product CybroCell, announced that the U.S. FDA had cleared its investigational new drug (IND) protocol of CybroCell for human trials in the U.S., considered to be the first IND approval for a fibroblast cell therapy in a chronic condition of degenerative disc disease.
Key features of the study:
- This report provides in-depth analysis of the U.S. degenerative disc disease treatment market, and provides market size (Mn patients) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the U.S. degenerative disc disease treatment market based on the following parameters – company highlights, financial overview, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include AnGes Inc., Ankasa Regenerative Therapeutics, Inc., BIOPHARM GMBH, BioRestorative Therapies Inc., Biosplice Therapeutics, Inc., Bone Therapeutics SA, Cerapedics Inc, CO.DON, Creative Medical Technology Holdings, Inc., DiscGenics Inc., Eli Lilly and Company, Ferring Pharmaceuticals, FibroGenesis, Geistlich Pharma AG, Harbor View Medical Services, PC, Intralink-Spine, Inc., Isto Biologics, Johnson & Johnson, Kolon TissueGene Inc., Kunovus, Lineage Cell Therapeutics, Inc., Mesoblast, NC Biomatrix BV, Notogen Inc., Pfizer, Inc., R3 Stem Cell, Smith & Nephew, Spine BioPharma, Stayble Therapeutics AB, US Stem Cell Inc., and VIVEX Biologics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The U.S. degenerative disc disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. degenerative disc disease treatment market
Detailed Segmentation:
- U.S. Degenerative Disc Disease Treatment Market, By Treatment:
- By Treatment :
- Epidural Steroid Injections
- Narcotics
- Morphine
- Methadone Hydrochloride
- Codeine
- Hydrocodone
- Tramodol
- Oxycodone
- Others
- Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products)
- Phase I
- Phase II
- Phase III
- U.S. Degenerative Disc Disease Treatment Market, By Disease Indication :
-
- Early Stage
- Mid Stage
- Late Stage
- U.S. Degenerative Disc Disease Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- AnGes Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Overview
- Strategy
- Ankasa Regenerative Therapeutics, Inc.
- BIOPHARM GMBH
- BioRestorative Therapies Inc.
- Biosplice Therapeutics, Inc.
- Bone Therapeutics SA
- Cerapedics Inc.
- DON
- Creative Medical Technology Holdings, Inc.
- DiscGenics Inc.
- Eli Lilly and Company
- Ferring Pharmaceuticals
- FibroGenesis
- Geistlich Pharma AG
- Harbor View Medical Services, PC
- Intralink-Spine, Inc.
- Isto Biologics
- Johnson & Johnson
- Kolon TissueGene Inc.
- Kunovus
- Lineage Cell Therapeutics, Inc.
- Mesoblast
- NC Biomatrix BV
- Notogen Inc.
- Pfizer, Inc.
- R3 Stem Cell
- Smith & Nephew
- Spine BioPharma
- Stayble Therapeutics AB
- US Stem Cell Inc.
- VIVEX Biologics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
